Ascendis Pharma A/S (ASND): Next-Year EPS Estimate 198.54%
As of 2026-05-07, Ascendis Pharma A/S (ASND) has a next-year EPS growth estimate of 198.54%.
On 2026-05-07, analyst consensus for ASND's next-year EPS growth shifted from 151.28% to 198.54% — a positive change of 47.26 percentage points. Current-year growth is projected at 183.99%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 198.54%
- EPS growth this year
- 183.99%
- EPS next quarter (est)
- $0.86
- Last price
- $246.14
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-07 | 198.54% | 183.99% | $0.86 | $246.14 |
| 2026-05-06 | 151.28% | 203.71% | $0.19 | $235.90 |
| 2026-05-05 | 150.93% | 204.08% | $0.20 | $225.28 |
| 2026-05-04 | 150.94% | 203.69% | $0.20 | $228.71 |
| 2026-05-03 | 150.94% | 203.71% | $0.20 | $220.93 |
| 2026-04-30 | 150.94% | 204.13% | $0.20 | $229.38 |
| 2026-04-29 | 150.94% | 203.85% | $0.20 | $220.28 |
| 2026-04-28 | 150.94% | 203.78% | $0.20 | $222.08 |
| 2026-04-27 | 150.57% | 203.94% | $0.20 | $226.66 |
| 2026-04-26 | 150.56% | 204.13% | $0.20 | $229.27 |
| 2026-04-24 | 150.56% | 204.13% | $0.20 | $229.27 |
| 2026-04-23 | 150.56% | 204.26% | $0.20 | $225.00 |
| 2026-04-22 | 150.31% | 204.45% | $0.22 | $231.05 |
| 2026-04-21 | 150.31% | 204.04% | $0.22 | $240.29 |
| 2026-04-20 | 150.31% | 204.49% | $0.22 | $245.38 |
| 2026-04-19 | 141.48% | 209.63% | $0.20 | $244.48 |
| 2026-04-16 | 141.48% | 209.48% | $0.20 | $242.95 |
| 2026-04-15 | 143.64% | 206.82% | $0.22 | $241.71 |
| 2026-04-14 | 143.64% | 207.10% | $0.22 | $249.84 |
| 2026-04-13 | 140.45% | 209.49% | $0.24 | $248.55 |
| 2026-04-12 | 139.91% | 209.51% | $0.25 | $239.28 |
| 2026-04-10 | 139.91% | 209.51% | $0.25 | $239.56 |
| 2026-04-09 | 139.91% | 209.82% | $0.25 | $241.71 |
| 2026-04-08 | 151.16% | N/A | $0.28 | $233.20 |
| 2026-04-07 | 151.16% | N/A | $0.28 | $220.48 |
| 2026-04-06 | 151.16% | N/A | $0.28 | $220.48 |
| 2026-04-05 | 153.11% | N/A | $0.31 | $229.25 |
| 2026-04-03 | 151.16% | N/A | $0.28 | $220.48 |
| 2026-04-02 | 151.16% | N/A | $0.28 | $220.48 |
| 2026-04-01 | 151.16% | N/A | $0.28 | $220.48 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Ascendis Pharma A/S's next-year EPS growth estimate?▾
As of 2026-05-07, Ascendis Pharma A/S (ASND) has a next-year EPS growth estimate of 198.54%, based on analyst consensus.
When was the latest EPS estimate revision for ASND?▾
The most recent revision occurred on 2026-05-07, when analysts adjusted the next-year EPS growth estimate from 151.28% to 198.54%.
What sector and industry does Ascendis Pharma A/S belong to?▾
Ascendis Pharma A/S operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ASND appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Ascendis Pharma A/S (ASND) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports